Celgene Corp., of Summit, N.J., said Health Canada approved Abraxane for injectable suspension (nab-paclitaxel powder for injectable suspension) in combination with gemcitabine as first-line treatment for adults with metastatic pancreatic cancer, based on the results of the phase III MPACT (Metastatic Pancreatic Adenocarcinoma Clinical Trial) study of 861 chemotherapy-naïve patients with metastatic pancreatic cancer from 11 countries, including Canada.